Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
XCUR - Exicure, Inc.
Market Cap 8.30M P/E 1.19 EPS this Y - Ern Qtrly Grth -
Income -8.17M Forward P/E -1.25 EPS next Y - 50D Avg Chg -11.00%
Sales 500k PEG - EPS past 5Y - 200D Avg Chg -16.00%
Dividend N/A Price/Book 0.55 EPS next 5Y - 52W High Chg -70.00%
Recommedations 3.00 Quick Ratio 0.32 Shares Outstanding 2.17M 52W Low Chg 52.00%
Insider Own 58.73% ROA -26.41% Shares Float 714.16K Beta 1.24
Inst Own 6.21% ROE -144.41% Shares Shorted/Prior 32.55K/37.58K Price 0.96
Gross Margin 100.00% Profit Margin - Avg. Volume 39,617 Target Price -
Oper. Margin -1,193.20% Earnings Date Aug 13 Volume 18,902 Change -0.91%
Healthcare | Biotechnology | United States
About Exicure, Inc.

Exicure, Inc. does not have significant operations. previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Exicure, Inc. News
12/21/24 CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes
11/14/24 Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results
09/18/24 Exicure, Inc. Receives Extension from Nasdaq Hearings Panel
09/09/24 Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation
08:08 AM Exicure, Inc. Announces 1-for-5 Reverse Stock Split
08/19/24 Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting
08/15/24 Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
08/13/24 Exicure, Inc. Reports Second Quarter 2024 Financial Results
08/08/24 Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics
08/01/24 Exicure, Inc. Receives Positive Listing Determination from Nasdaq
06/17/24 Exicure, Inc. Reports First Quarter 2024 Financial Results
06/06/24 Exicure, Inc. Reports Full Year 2023 Financial Results
05/23/24 Exicure, Inc. Received Nasdaq Notice of a Delisting Determination
05/16/24 Exicure, Inc. Reports Third Quarter 2023 Financial Results
04/22/24 Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
02/05/24 Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis